
About Renalytix Tech
Renalytix Tech is a publicly listed company based in New York (United States) founded in 2018 by Girish Nadkarni. Provider of AI-based kidney disease diagnosis tool for healthcare professionals. Renalytix Tech offers products and services including KidneyIntelX.dkd. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its legal entity is Renalytix Clinical Laboratories. Its competitors include PaxeraHealth, Bio-AI Health and Visla Labs; 2 of its 3 listed competitors have raised funding.
Company details
Renalytix Tech was founded in 2018 in New York, United States, as a provider in the healthcare sector focused on AI-driven solutions for kidney disease. Software such as KidneyIntelX is utilized by clinics to analyze medical data, monitor treatment progress, assess risks, and generate AI-based scores for disease progression. Operations emphasize diagnostic support for professionals, with features tailored to kidney measurements and overall patient risk evaluation.
- Headquarters New York, United States
- Founders Girish Nadkarni
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website renalytix.com
- Social LinkedIn X
- Legal Name Renalytix Plc
- Annual Revenue$3.18 M (USD)26.93as on Jun 30, 2025
- Net Profit-$21.6 M (USD)56.37as on Jun 30, 2025
- EBITDA-$18.22 M (USD)40.22as on Jun 30, 2025
- Latest Funding Round$20.3M (USD), Post-IPO
Feb 2023
Products & Services of Renalytix Tech
Renalytix Tech offers a comprehensive portfolio of products and services, including KidneyIntelX.dkd.
Predicts risk of kidney function decline in diabetic patients over five years.
Funding Insights of Renalytix Tech
- Total Rounds 1
- Last Round Post-IPO β $20.3M
- First Round $20.3M
(Feb 2023)
All 1 funding rounds of Renalytix Tech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $20.3M | Post-IPO | β | β | β |
People of Renalytix Tech
21 people are tracked at Renalytix Tech (8 in leadership, 6 in board & advisors, 7 in team).
| Name | Role | Group |
|---|---|---|
Girish Nadkarni | Co-Founder | Leadership |
James McCullough | CEO | Leadership |
Michael J. Donovan | Chief Medical Officer | Leadership |
Christopher Scott | Chief Operating Officer | Leadership |
Fergus Fleming | CTO | Leadership |
Adrian Rossouw | Vice President Of Information Systems And Product | Leadership |
Anna Flynn | Director, Quality System Compliance And Eh&s | Leadership |
Elise Wilfinger | Chief Strategy & Marketing Officer | Leadership |
Timothy J. Scannell | Non-Executive Directors | Board & advisors |
Chirag R. Parikh | Non-Executive Director | Board & advisors |
Christopher Mills | Non-Executive Director | Board & advisors |
Erik Lium | Non-Executive Director | Board & advisors |
Daniel J. Levangie | Non-Executive Director | Board & advisors |
Catherine Coste | Director | Board & advisors |
Azadeh Zabetian | Senior Medical Science Liaison | Team |
Christopher Woytovich | Clinical Laboratory Scientist (cls) | Team |
Anita M. | Lab Technical Supervisor | Team |
Greg Schallert | Product Manager, Digital Health Solutions | Team |
Andrew Peabody | Product Manager, Digital Health Solutions | Team |
Kate Benkoczy | Manager, Health System Partnerships | Team |
1 more people are available in the full profile.
Complete people profiles for Renalytix Tech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Renalytix Tech
Renalytix Tech is a publicly listed company on the LSE with ticker symbol RENX in UK, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Jul 2020
- Listed onNASDAQ: RNLX
- Listed entityRenalytix Plc
- Exchange sectorTechnology services
- ISINGB00BYWL4Y04
- Share price5.35 GBX · 2026-10-14
- Market capitalisation35,869,572.00 GBX
Financials of Renalytix Tech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.3M GBP | -15.8M GBP | -13.3M GBP |
| 2024 | 1.8M GBP | -36.1M GBP | -22.2M GBP |
| 2023 | 2.8M GBP | -37.9M GBP | -34.7M GBP |
| 2022 | 2.2M GBP | -34.1M GBP | -39.6M GBP |
| 2021 | 1.1M GBP | -25.8M GBP | -22.8M GBP |
Detailed financial statements for Renalytix Tech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Renalytix Tech
3 dated milestones of Renalytix Tech across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Renalytix Tech is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $20.3M.
Competitors of Renalytix Tech
Renalytix Tech has 3 listed competitors in our database, 2 of them funded. They include PaxeraHealth, Bio-AI Health and Visla Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| paxerahealth.com | 2009 | Boston, United States | $5.5M | AI-based medical image management solutions are offered for organizations. | ||
| bioaihealth.com | 2020 | Goffstown, United States | $3.5M | AI-based disease diagnosis is provided for healthcare professionals. | ||
| visla.ai | 2018 | San Francisco, United States | Functions as an AI-based tool for disease diagnosis in healthcare. |
Detailed competitors of Renalytix Tech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Renalytix Tech
The website of Renalytix Tech (renalytix.com) receives about 3.8K visits a month.
- Monthly visits3.8K
▲ 14.3% vs previous month
Top companies in Clinical IT & Data Platforms
3 companies that operate in the same segment as Renalytix Tech (Clinical IT & Data Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | |||
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | 1,746 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Renalytix Tech
Complete news archive for Renalytix Tech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renalytix Tech
Renalytix Tech was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Renalytix Tech is headquartered in New York, United States. It is registered at New York, New York, United States.
Annual revenue of Renalytix Tech is $3.18M as on Jun 30, 2025.
Renalytix Tech was founded in 2018 in New York, United States, as a provider in the healthcare sector focused on AI-driven solutions for kidney disease. Software such as KidneyIntelX is utilized by clinics to analyze medical data, monitor treatment progress, assess risks, and generate AI-based scores for disease progression. Operations emphasize diagnostic support for professionals, with features tailored to kidney measurements and overall patient risk evaluation.
Renalytix Tech's top competitors include Bio-AI Health, PaxeraHealth and Visla Labs.
Renalytix Tech offers KidneyIntelX.dkd.
Yes, Renalytix Tech is publicly traded on LSE under the ticker symbol RENX.
Renalytix Tech operates through Renalytix Clinical Laboratories.
